Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1794 • ACR Convergence 2023
The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis
Archita Srinath¹, Daniele Mauro², Francesco Ciccia³ and Nigil Haroon⁴, ¹University of Toronto, Toronto, ON, Canada, ²University of Campania, Naples, Italy, ³University of Campania - Luigi Vanvitelli, Naples, Italy, ⁴University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Medicine/Rheumatology, Toronto, ON, Canada
Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…
Abstract Number: 0520 • ACR Convergence 2023
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
Sofia Ramiro¹, Cedric Lukas², Louis Bessette³, Pendleton Wickersham⁴, Soyi Liu-Leage⁵, Tommaso Panni⁵, Rebecca Bolce⁵, Boris Janos⁵, Michael Nissen⁶ and James Cheng-Chung Wei⁷, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²CHU Montpellier, Montpellier, France, ³Centre de l'Ostéoporose et de Rhumatologie de Québec, Quebec City, QC, Canada, ⁴Arthritis Associates PA, San Antonio, TX, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Geneva University Hospitals, Geneva, Switzerland, ⁷Chung Shan Medical University Hospital, Department of Rheumatology, Taichung, Taiwan
Background/Purpose: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response…
Abstract Number: 1032 • ACR Convergence 2023
“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)
Bryanna Mantilla¹, K Wysham², Jean liew³ and Grant Hughes¹, ¹University of Washington, Seattle, WA, ²VA Puget Sound/University of Washington, Seattle, WA, ³Boston University, Boston, MA
Background/Purpose: Axial spondyloarthritis (axSpA) can result in significant morbidity. Existing studies suggest functional impairment and inflammation may be worse in Black and Latine patients. However,…
Abstract Number: 1403 • ACR Convergence 2023
MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Kristyna Bubova¹, Lenka Hasikova², Katerina Mintalova², Monika Gregova², Sarka Forejtova², Ladislav Senolt³ and Karel Pavelka⁴, ¹Institute of Rheumatology, Prague, Czech Republic, ²Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Prague, Czech Republic, ³Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁴Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic
Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) - the inflammatory rheumatic disease with a strong genetic background. The aim of this…
Abstract Number: 1854 • ACR Convergence 2023
What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort
Gurdeep Dulay¹, Antoni Chan², Catherine Boys³, Aisling Coy⁴, Mary Devin⁵, Leslie Goh⁶, Arran McDougall², Kathryn Rigler², Jacqui Tomkins⁷, Dinny Wallis⁷ and Emma Williams⁸, ¹Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ²Royal Berkshire NHS Foundation Trust, Reading, United Kingdom, ³NHS, Basingstoke, United Kingdom, ⁴Salisbury NHS Foundation Trust, Salisbury, United Kingdom, ⁵Dorset County Hospital NHS, Dorchester, United Kingdom, ⁶NHS, Portsmouth, United Kingdom, ⁷NHS, Southampton, United Kingdom, ⁸NHS, Winchester, United Kingdom
Background/Purpose: Due to the insidious onset of axial spondyloarthritis (AxSpA), there is often a significant delay to diagnosis. The average delay to diagnosis in the…
Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Martin Rudwaleit¹, Victoria Navarro-Compán², Atul Deodhar³, Maureen Dubreuil⁴, Michael Frank Mørup⁵, Vanessa Taieb⁶, Christine de la Loge⁷, Carmen Fleurinck⁸, Ute Massow⁹, Thomas Vaux¹⁰ and Annelies Boonen¹¹, ¹University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ²Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ³Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA, ⁵UCB Pharma, Copenhagen, Denmark, ⁶UCB Pharma, Colombes, France, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Oosterzele, Belgium, ⁹UCB Pharma, Monheim am Rhein, Germany, ¹⁰UCB Pharma, Slough, United Kingdom, ¹¹Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…
Abstract Number: 1209 • ACR Convergence 2023
The Role of Kinesiophobia on Ankylosing Spondylitis Disease Activity, Exercise Habits, and Quality of Life
Joel Thompson, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose: Patients with Ankylosing Spondylitis (AS) consistently report exercise frequencies that are lower than healthy controls and ACSM/EULAR recommended frequencies; even though exercise has consistently…
Abstract Number: 1404 • ACR Convergence 2023
Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis
Chang-Nam Son¹, Ji-Hyun Lee¹, Sungsin Jo² and Tae-Hwan Kim³, ¹Uijeongbu Eulji Medical Center, Eulji University School of Medicine, UIJEONGBU, South Korea, ²Hanyang University Institute for Rheumatology Research, Seoul, South Korea, ³Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: The complement factor H-related protein-5 (FHR-5), a member of the human factor H protein family, enhances complement activation. The influence of complement activation on…
Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Alyssa Howren¹, Eric Sayre², J. Antonio Avina-Zubieta³, Joseph Puyat¹, Deborah Da Costa⁴, Hui Xie⁵, Amit Gupta¹ and Mary De Vera¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Centre on Substance Use, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada, ⁴McGill University, Pointe-Claire, QC, Canada, ⁵Simon Fraser University, Richmond, BC, Canada
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…
Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Marina Nighat Magrey¹, Marleen van de Sande², Maxime Breban³, Filip Van den Bosch⁴, Carmen Fleurinck⁵, Ute Massow⁶, Natasha De Peyrecave⁷, Thomas Vaux⁸, Xenofon Baraliakos⁹ and Helena Marzo-Ortega¹⁰, ¹Case Western Reserve University, University Hospitals, Cleveland, OH, ²Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ³CHU Ambroise-Paré, Boulogne-Billancourt, Paris, France, ⁴Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁵UCB Pharma, Oosterzele, Belgium, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Slough, United Kingdom, ⁹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ¹⁰NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…
Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Zeynep Toker Dincer, Bahaddin Ates, Ayten Dag, Ilayda Turkoglu, Ali Yagiz Ayla and Serdal Ugurlu, Istanbul University-Cerrahpasa, Istanbul, Turkey
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…
Abstract Number: 1405 • ACR Convergence 2023
Diagnostic Delay of Axial Spondyloarthritis in African American Patients
John Byun¹, Hans Vitzthum von Eckstaedt¹, Kichul Ko² and Reem Jan¹, ¹University of Chicago, Chicago, IL, ²The University of Chicago, Chicago, IL
Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…
Abstract Number: 1892 • ACR Convergence 2023
Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
De Meester Liesbet¹, Gaelle Varkas², Manouk de Hooge³, Ann-Sophie De Craemer⁴, Nele Herregods⁵, Lennart Jans⁵, Philippe Carron⁶, Dirk Elewaut⁷ and Filip Van den Bosch⁸, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Dept. of Rheumatology, Ghent University Hospital, Ghent, Belgium, ³Ghent University Hospital, Hesperange, Luxembourg, ⁴Ghent University Hospital, Gent, Belgium, ⁵Department of Radiology, Ghent University Hospital, Ghent, Belgium, ⁶UZ Gent, Gent, Belgium, ⁷Ghent University and VIB Center for Inflammation Research, Ghent, Belgium, ⁸Department of Internal Medicine and Pediatrics, Ghent University and VIB Center for Inflammation Research, Ghent, Belgium
Background/Purpose: Sacroiliac bone marrow oedema (BMO) on MRI, immediately after childbirth, has been observed in a large proportion of postpartum women and appears to be…
Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Maureen Dubreuil¹, Karl Gaffney², Jonathan Kay³, Victoria Navarro-Compán⁴, Christine de la Loge⁵, Alicia Ellis⁶, Carmen Fleurinck⁷, Ute Massow⁸, Vanessa Taieb⁹ and Atul Deodhar¹⁰, ¹Department of Rheumatology, Boston University School of Medicine, Milton, MA, ²Norfolk and Norwich University Hospital NHS Trust, Norfolk, United Kingdom, ³Division of Rheumatology, Department of Medicine, UMass Chan Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁵UCB Pharma, Brussels, Belgium, ⁶UCB Pharma, Raleigh, NC, ⁷UCB Pharma, Oosterzele, Belgium, ⁸UCB Pharma, Monheim am Rhein, Germany, ⁹UCB Pharma, Colombes, France, ¹⁰Division of Arthritis and Rheumatic Disease, Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…
Abstract Number: 1383 • ACR Convergence 2023
Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Kwi Young Kang¹ and Hyoun-Ah Kim², ¹Catholic University of Korea, Seoul, South Korea, ²Ajou University School of Medicine, Suwon, South Korea
Background/Purpose: To assess the longitudinal association between physical activity and global functioning in patients with axial spondyloarthritis (axSpA) and to identify the subtype of physical…

« Previous Page
1
…
8
9
10
11
12
…
62
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].